Hodgkin's Survivor Climbs French Mountain

Hodgkin's lymphoma survivor David Couch was thwarted in the first leg of his fundraising effort for a cancer hospital when an avalanche struck on Mont Blanc. Couch was diagnosed with Hodgkin's disease in 2002 but recovered after three years' chemotherapy and radiology treatment at the Royal Marsden hospital in the UK. Mrl. Couch decided to run two half-marathons and climb the French mountain to raise money for the Chelsea hospital.




Last weekend the 34-year-old surveyor was less than 50 metres from the top of the Mont Blanc du Tacul ridge when he was forced to turn back.



Mr Couch said: "I was doing it with five friends and none of us had mountaineering experience, although we did have a guide. If we had left a few hours earlier, we would have been caught in (an) avalanche. It felt much higher and steeper than I thought it would. If you fall, you can fall several thousand metres. We were pretty near the top. We were more frustrated than anything else, but our guide was sensible and said we should turn back. It made us realise how dangerous the mountain could be."



Mr Couch has raised 6,500 Pounds so far for the hospital and hopes to top 10,000 Pounds. Amanda Heaton, Royal Marsden fundraising manager, said: "We are bowled over by the extraordinary lengths David is going to for our cancer campaign."

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap